Impiego di un’associazione fissa di formoterolo e budesonide nel trattamento del paziente asmatico
- First Online:
- Cite this article as:
- Lucioni, C., Mangrella, M., Mazzi, S. et al. Pharmacoeconomics-Ital-Res-Articles (2002) 4: 15. doi:10.1007/BF03320590
- 1 Downloads
Treatment of patients with asthma with a fixed combination of budesonide and formoterol: a pharmacoeconomic evaluation vs some therapeutic alternatives
To evaluate the cost-effectiveness of a fixed combination of budesonide and formoterol (B/F) in one inhaler for the treatment of patients with asthma in the framework of some case studies.
Materials and methods
B/F was compared: 1) with the free association of budesonide and formoterol, based on Swedish clinical data derived from the COMSAFE trial, an international, open, randomised, controlled study. Resources use and loss of productivity were evaluated by means of costs and tariffs from the Italian healthcare and economic systems; 2) with fluticasone, on the basis of data from another international, randomised, double blind, double dummy study. In this case too costs and tariffs applied were the ones current in Italy.
The societal perspective was adopted.
Treatment with B/F resulted more convenient (in terms of costs saved) versus treatment with either budesonide and formoterol in two separate inhalers or fluticasone. Average total (direct and indirect) costs saved by using B/F compared with budesonide and formoterol in separate inhalers were € 119, for each patient treated for 6 months. € 130 were saved (40% of which being medical costs) when one patient was treated with B/F instead of fluticasone over a period of 12 weeks.
Such cost-minimisation analyses show some non negligible elements of economic convenience in choosing B/F for the treatment of patients with asthma.